JENA, Germany, May 12 /CNW/ - Occlutech GmbH, a leading European
developer of minimally invasive implants for the treatment of
structural heart disease, today announced that it has received a
favourable court ruling from the German Supreme Court, (BGH), in
Karlsruhe, Gerrmany in patent litigation initiated by AGA Medical Inc.,
now part of St. Jude Medical Inc.
In the ruling by the BGH, the court does not see any basis for AGA / St.
Jude's claim that the Occlutech ASD and PFO occluders violate any
patent brought forward in the litigation and declares earlier German
ruling to the contrary invalid. The German Supreme Court ruling is
similar in many aspects to the first instance ruling in the UK which
was confirmed by the appeal court in the UK in mid 2010. The UK ruling
is final as the UK Supreme Court did not allow an appeal requested by
AGA. The favourable German ruling is also similar to first instance, as
well as appeal court decisions in The Hague, in The Netherlands, the
last one obtained at the end of 2010 as well as a district court ruling
in Stockholm, Sweden obtained in March 2011.
Throughout the litigation, Occlutech's owners and partners have funded
work in maintaining and substantially strengthening Occlutech's own
patent position. Meanwhile, a full pipeline of new technologies and
products have been developed. In 2011 and 2012 Occlutech expects to
launch additional occluders for indications such as PDA and VSD in
addition to second generation ASD and PFO occluders. Also, an
innovative LAA occluder, a new generation of stent grafts and cardiac
valve intervention technologies are being developed.
Occlutech intends to initiate litigation for substantial damages against
AGA / St. Jude.
SOURCE Occlutech GmbH
For further information:
Tor Peters, +49-3641-67-51-29, email@example.com; Katrin Biedermann, +49-3641-67-51-20, firstname.lastname@example.org